MicroRNAs as the fine-tuners of Src oncogenic signalling

Journal of Biochemistry

Volumn 157, Issue 6, 2015, Pages 431-438

  Oneyama, Chitose ^a,b   Okada, Masato ^b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Cancer signalling; MicroRNA; MTOR; Proto oncogene; Src

Indexed keywords

CRK LIKE PROTEIN; INHIBITOR OF DIFFERENTIATION 1; INTEGRIN LINKED KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 126; MICRORNA 203; MICRORNA 205; MICRORNA 23B; MICRORNA 27B; MICRORNA 29B; MICRORNA 30; MICRORNA 31; MICRORNA 424; MICRORNA 503; MICRORNA 542 3P; MICRORNA 99A; PAXILLIN; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; PROTEIN KINASE P60;

CANCER GENETICS; CANCER GROWTH; CARCINOGENESIS; ELECTRORETINOGRAM; FOCAL ADHESION; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; MOLECULAR PATHOLOGY; NEOPLASM; ONCOGENE; ONCOGENE SRC; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAIN; DISEASE COURSE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

DISEASE PROGRESSION; HUMANS; MICRORNAS; NEOPLASMS; ONCOGENES; PROTO-ONCOGENE PROTEINS PP60(C-SRC); SIGNAL TRANSDUCTION;

EID: 84943767095     PISSN: 0021924X     EISSN: 17562651     Source Type: Journal    
DOI: 10.1093/jb/mvv036     Document Type: Review

References (77)

1. Jove, R. and Hanafusa, H. (1987) Cell transformation by the viral src oncogene. Annu. Rev. Cell. Biol. 3, 31-56
2. Summy, J.M. and Gallick, G.E. (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 22, 337-358
3. Yeatman, T.J. (2004) A renaissance for SRC. Nat. Rev. Cancer 4, 470-480
4. Frame, M.C. (2004) Newest findings on the oldest oncogene; how activated src does it. J. Cell Sci. 117, 989-998
5. Kim, L.C., Song, L., and Haura, E.B. (2009) Src kinases as therapeutic targets for cancer. Nat. Rev. Clin. Oncol. 6, 587-595
6. Krishnan, H., Miller, W.T., and Goldberg, GS. (2012) SRC points the way to biomarkers and chemotherapeutic targets. Genes Cancer 3, 426-435
7. Edwards, J. (2010) Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer. Expert Opin. Investig. Drugs 19, 605-614
8. Brown, M. and Cooper, J. (1996) Regulation, substrates and functions of src. Biochim. Biophys. Acta 1287, 121-149
9. Playford, M.P. and Schaller, M.D. (2004) The interplay between Src and integrins in normal and tumor biology. Oncogene 23, 7928-7946
10. Okada, M. (2012) Regulation of the SRC family kinases by Csk. Int. J. Biol. Sci. 8, 1385-1397
11. Senga, T., Miyazaki, K., Machida, K., Iwata, H., Matsuda, S., Nakashima, I., and Hamaguchi, M. (2000) Clustered cysteine residues in the kinase domain of v-Src: critical role for protein stability, cell transformation and sensitivity to herbimycin A. Oncogene 19, 273-279
12. Laszlo, GS. and Cooper, J.A. (2009) Restriction of Src activity by Cullin-5. Curr. Biol. 19, 157-162
13. Hakak, Y. and Martin, GS. (1999) Ubiquitin-dependent degradation of active Src. Curr. Biol. 9, 1039-1042
14. Martin, GS. (2004) The road to Src. Oncogene 23, 7910-7917
15. Irby, R. and Yeatman, T. (2000) Role of Src expression and activation in human cancer. Oncogene 19, 5636-5642
16. Arcaroli, J.J., Touban, B.M., Tan, A.C., Varella-Garcia, M., Powell, R.W., Eckhardt, S.G, Elvin, P., Gao, D., and Messersmith, W.A. (2010) Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer. Clin. Cancer Res. 16, 4165-4177
17. Oneyama, C, Hikita, T., Nada, S., and Okada, M. (2008) Functional dissection of transformation by c-Src and v-Src. Genes Cells 13, 1-12
18. Oneyama, C, Hikita, T., Enya, K., Dobenecker, M.W., Saito, K., Nada, S., Tarakhovsky, A., and Okada, M. (2008) The lipid raft-anchored adaptor protein Cbp controls the oncogenic potential of c-Src. Mol. Cell. 30, 426-436
19. Oneyama, C, Iino, T., Saito, K., Suzuki, K., Ogawa, A., and Okada, M. (2009) Transforming potential of Src family kinases is limited by the cholesterol-enriched membrane microdomain. Mol. Cell. Biol. 29, 6462-6472
20. Ha, M. and Kim, V.N. (2014) Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell. Biol. 15, 509-524
21. Guo, H., Ingolia, N.T., Weissman, J.S., and Bartel, D.P. (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466, 835-840
22. Kunej, T., Godnic, I., Horvat, S., Zorc, M., and Calin, G.A. (2012) Cross talk between microRNA and coding cancer genes. Cancer J. 18, 223-231
23. Di Leva, G. and Croce, CM. (2013) miRNA profiling of cancer. Curr. Opin. Genet. Dev. 23, 3-11
24. Zhang, B., Pan, X., Cobb, G.P., and Anderson, T.A. (2007) microRNAs as oncogenes and tumor suppressors. Dev. Biol. 302, 1-12
25. Oom, A.L., Humphries, B.A., and Yang, C. (2014) MicroRNAs: novel players in cancer diagnosis and therapies. Biomed. Res. Int. 2014, 959461
26. Oneyama, C, Ikeda, J., Okuzaki, D., Suzuki, K., Kanou, T., Shintani, Y., Morii, E., Okumura, M., Aozasa, K., and Okada, M. (2011) MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene 30, 3489-3501
27. Calin, GA. and Croce, CM. (2006) MicroRNA signatures in human cancers. Nat. Rev. Cancer. 6, 857-866
28. Wullschleger, S., Loewith, R., and Hall, M.N. (2006) TOR signaling in growth and metabolism. Cell 124, 471-484
29. Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J.L., Bonenfant, D., Oppliger, W., Jenoe, P., and Hall, M.N. (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10, 457-468
30. Mamane, Y., Petroulakis, E., LeBacquer, O., and Sonenberg, N. (2006) mTOR, translation initiation and cancer. Oncogene 25, 6416-6422
31. Sarbassov, D.D., Guertin, D.A., Ali, S.M., and Sabatini, D.M. (2005) Phosphorylation and regulation of Akt/ PKB by the rictor-mTOR complex. Science 307, 1098-1101
32. Guertin, D.A. and Sabatini, D.M. (2007) Defining the role of mTOR in cancer. Cancer Cell 12, 9-22
33. Liu, Q., Thoreen, C, Wang, J., Sabatini, D., and Gray, N.S. (2009) mTOR mediated anti-cancer drug discovery. Drug. Discov. Today Ther. Strateg. 6, 47-55
34. Yamada, H, Yanagisawa, K., Tokumaru, S., Taguchi, A., Nimura, Y., Osada, H., Nagino, M., and Takahashi, T. (2008) Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at 21q11-21 in human lung cancer. Genes Chromosomes Cancer 47, 810-818
35. Engelman, J.A. (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9, 550-562
36. Doghman, M., El Wakil, A., Cardinaud, B., Thomas, E., Wang, J., Zhao, W., Peralta-Del Valle, M.H., Figueiredo, B.C., Zambetti, G.P., and Lalli, E. (2010) Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res. 70, 4666-4675
37. Fornari, F., Milazzo, M., Chieco, P., Negrini, M., Calin, G.A., Grazi, GL., Pollutri, D., Croce, CM, Bolondi, L., and Gramantieri, L. (2010) MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 70, 5184-5193
38. Nagaraja, A.K., Creighton, C.J., Yu, Z., Zhu, H, Gunaratne, P.H., Reid, J.G, Olokpa, E., Itamochi, H, Ueno, N.T., Hawkins, S.M., Anderson, M.L., and Matzuk, M.M. (2010) A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol. Endocrinol. 24, 447-463
39. Oneyama, C, Kito, Y., Asai, R., Ikeda, J., Yoshida, T., Okuzaki, D., Kokuda, R., Kakumoto, K., Takayama, K., Inoue, S., Morii, E., and Okada, M. (2013) MiR-424/503-mediated Rictor upregulation promotes tumor progression. PLoS One 8, e80300
40. Tsuruta, T., Kozaki, K., Uesugi, A., Furuta, M., Hirasawa, A., Imoto, I., Susumu, N, Aoki, D., and Inazawa, J. (2011) miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res. 71, 6450-6462
41. Uesugi, A., Kozaki, K., Tsuruta, T., Furuta, M., Morita, K., Imoto, I., Omura, K., and Inazawa, J. (2011) The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res. 71, 5765-5778
42. Mitra, S.K. and Schlaepfer, D.D. (2006) Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell. Biol. 18, 516-523
43. Frame, M., Fincham, V., Carragher, N, and Wyke, J. (2002) v-Src's hold over actin and cell adhesions. Nat. Rev. Mol. Cell. Biol. 3, 233-245
44. Hannigan, G.E., Leung-Hagesteijn, C, Fitz-Gibbon, L., Coppolino, M.G, Radeva, G, Filmus, J., Bell, J.C., and Dedhar, S. (1996) Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 379, 91-96
45. Hannigan, G, Troussard, A.A., and Dedhar, S. (2005) Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat. Rev. Cancer 5, 51-63
46. McDonald, P.C., Fielding, A.B., and Dedhar, S. (2008) Integrin-linked kinase-essential roles in physiology and cancer biology. J. Cell. Sci. 121, 3121-3132
47. Oneyama, C, Morii, E., Okuzaki, D., Takahashi, Y., Ikeda, J., Wakabayashi, N, Akamatsu, H., Tsujimoto, M., Nishida, T., Aozasa, K, and Okada, M. (2012) MicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression. Oncogene 31, 1623-1635
48. Taylor, B.S., Schultz, N, Hieronymus, H, Gopalan, A., Xiao, Y., Carver, B.S., Arora, V.K., Kaushik, P., Cerami, E., Reva, B., Antipin, Y., Mitsiades, N, Landers, T., Dolgalev, I., Major, J.E., Wilson, M., Socci, N.D., Lash, A.E., Heguy, A., Eastham, J.A., Scher, H.I., Reuter, V.E., Scardino, P.T., Sander, C, Sawyers, C.L., and Gerald, W.L. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22
49. Navon, R., Wang, H., Steinfeld, I., Tsalenko, A., Ben-Dor, A., and Yakhini, Z. (2009) Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS One 4, e8003
50. Burridge, K, Turner, CE., and Romer, L.H. (1992) Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: a role in cytoskeletal assembly. J. Cell. Biol. 119, 893-903
51. Schaller, M.D. (2001) Paxillin: a focal adhesion-associated adaptor protein. Oncogene 20, 6459-6472
52. Azuma, K, Tanaka, M., Uekita, T., Inoue, S., Yokota, J., Ouchi, Y., and Sakai, R. (2005) Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcoma. Oncogene 24, 4754-4764
53. Shi, J., Wang, S., Zhao, E., Shi, L., Xu, X., and Fang, M. (2010) Paxillin expression levels are correlated with clinical stage and metastasis in salivary adenoid cystic carcinoma. J. Oral Pathol. Med. 39, 548-551
54. Fong, S., Debs, R.J., and Desprez, P.Y. (2004) Id genes and proteins as promising targets in cancer therapy. Trends Mol. Med. 10, 387-392
55. Rothschild, S.I., Tschan, M.P., Federzoni, E.A., Jaggi, R., Fey, M.F., Gugger, M., and Gautschi, O. (2012) MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma. Oncogene 31, 4221-4232
56. Tatarov, O., Mitchell, T.J., Seywright, M., Leung, H.Y., Brunton, V.G., and Edwards, J. (2009) SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin. Cancer Res. 15, 3540-3549
57. Yu, E.Y., Wilding, G, Posadas, E., Gross, M., Culine, S., Massard, C, Morris, M.J., Hudes, G, Calabro, F., Cheng, S., Trudel, G.C., Paliwal, P., and Sternberg, C.N. (2009) Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res. 15, 7421-7428
58. Kao, C.J., Martiniez, A., Shi, X.B., Yang, J., Evans, C.P., Dobi, A., deVere White, R.W., and Kung, H.J. (2014) miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene 33, 2495-2503
59. Li, X., Shen, Y., Ichikawa, H., Antes, T., and Goldberg, GS. (2009) Regulation of miRNA expression by Src and contact normalization: effects on nonanchored cell growth and migration. Oncogene 28, 4272-4283
60. Tsuda, M. and Tanaka, S. (2012) Roles for crk in cancer metastasis and invasion. Genes Cancer 3, 334-340
61. Donadelli, M., Dando, I., Fiorini, C, and Palmieri, M. (2014) Regulation of miR-23b expression and its dual role on ROS production and tumour development. Cancer Lett. 349, 107-113
62. Majid, S., Dar, A.A., Saini, S., Arora, S., Shahryari, V., Zaman, M.S., Chang, I., Yamamura, S., Tanaka, Y., Deng, G, and Dahiya, R. (2012) miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res. 72, 6435-6446
63. Yonezawa, Y., Nagashima, Y., Sato, H., Virgona, N., Fukumoto, K., Shirai, S., Hagiwara, H., Seki, T., Ariga, T., Senba, H., Suzuki, K., Asano, R., Hagiwara, K., and Yano, T. (2005) Contribution of the Src family of kinases to the appearance of malignant phenotypes in renal cancer cells. Mol. Carcinog. 43, 188-197
64. Majid, S., Saini, S., Dar, A.A., Hirata, H., Shahryari, V., Tanaka, Y., Yamamura, S., Ueno, K., Zaman, M.S., Singh, K., Chang, I., Deng, G, and Dahiya, R. (2011) MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res. 71, 2611-2621
65. Yoshida, T., Zhang, G, Smith, M.A., Lopez, A.S., Bai, Y., Li, J., Fang, B., Koomen, J., Rawal, B., Fisher, K.J., Chen, A.Y., Kitano, M., Morita, Y., Yamaguchi, H., Shibata, K., Okabe, T., Okamoto, I., Nakagawa, K., and Haura, E.B. (2014) Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer. Clin. Cancer Res. 20, 4059-4074
66. Ochi, N., Takigawa, N., Harada, D., Yasugi, M., Ichihara, E., Hotta, K., Tabata, M., Tanimoto, M., and Kiura, K. (2014) Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer. Exp. Cell Res. 322, 168-177
67. Bianco, C. and Salomon, D.S. (2010) Targeting the embryonic gene Cripto-1 in cancer and beyond. Expert Opin. Ther. Pat. 20, 1739-1749
68. Park, K.S., Raffeld, M., Moon, Y.W., Xi, L., Bianco, C, Pham, T., Lee, L.C., Mitsudomi, T., Yatabe, Y., Okamoto, I., Subramaniam, D., Mok, T., Rosell, R., Luo, J., Salomon, D.S., Wang, Y., and Giaccone, G (2014) CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. J. Clin. Invest. 124, 3003-3015
69. Veerla, S., Lindgren, D., Kvist, A., Frigyesi, A., Staaf, J., Persson, H., Liedberg, F., Chebil, G, Gudjonsson, S., Borg, A., Mansson, W., Rovira, C, and Hoglund, M. (2009) MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int. J. Cancer 124, 2236-2242
70. Augoff, K., McCue, B., Plow, E.F., and Sossey-Alaoui, K. (2012) miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triplenegative breast cancer. Mol. Cancer 11, 5
71. Cao, Q., Mani, R.S., Ateeq, B., Dhanasekaran, S.M., Asangani, I.A., Prensner, J.R., Kim, J.H., Brenner, J.C., Jing, X., Cao, X., Wang, R., Li, Y., Dahiya, A., Wang, L., Pandhi, M., Lonigro, R.J., Wu, Y.M., Tomlins, S.A., Palanisamy, N, Qin, Z., Yu, J., Maher, CA., Varambally, S., and Chinnaiyan, A.M. (2011) Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell 20, 187-199
72. Asangani, I.A., Harms, P.W., Dodson, L., Pandhi, M., Kunju, L.P., Maher, CA., Fullen, D.R., Johnson, T.M., Giordano, T.J., Palanisamy, N, and Chinnaiyan, A.M. (2012) Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget 3, 1011-1025
73. Rothschild, S.I., Gautschi, O., Haura, E.B., and Johnson, F.M. (2010) Src inhibitors in lung cancer: current status and future directions. Clin. Lung Cancer 11, 238-242
74. Wang, N, Liang, H., Zhou, Y., Wang, C, Zhang, S., Pan, Y., Wang, Y., Yan, X., Zhang, J., Zhang, C.Y., Zen, K, Li, D., and Chen, X. (2014) miR-203 suppresses the proliferation and migration and promotes the apoptosis of lung cancer cells by targeting SRC. PLoS One 9, e105570
75. Engelman, J.A., Zejnullahu, K, Mitsudomi, T., Song, Y., Hyland, C, Park, J.O., Lindeman, N, Gale, CM., Zhao, X., Christensen, J., Kosaka, T., Holmes, A.J., Rogers, A.M., Cappuzzo, F., Mok, T., Lee, C, Johnson, B.E., Cantley, L.C., and Janne, P.A. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043
76. Benedettini, E., Sholl, L.M., Peyton, M., Reilly, J., Ware, C, Davis, L., Vena, N, Bailey, D., Yeap, B.Y., Fiorentino, M., Ligon, A.H., Pan, B.S., Richon, V., Minna, J.D., Gazdar, A.F., Draetta, G, Bosari, S., Chirieac, L.R., Lutterbach, B., and Loda, M. (2010) Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am. J. Pathol. 177, 415-423
77. Garofalo, M., Romano, G, Di Leva, G, Nuovo, G, Jeon, Y.J., Ngankeu, A., Sun, J., Lovat, F., Alder, H., Condorelli, G, Engelman, J.A., Ono, M., Rho, J.K., Cascione, L., Volinia, S., Nephew, K.P., and Croce, CM. (2012) EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat. Med. 18, 74-82